Delcath Systems, Inc., a development stage company, operates as a specialty pharmaceutical and medical device company. It focuses on cancers in the liver. The company involves in the development and clinical study of the Delcath chemosaturation system. Its clinical trial include a Phase III multi-center study for patients with unresectable metastatic ocular or cutaneous melanoma exclusively or predominantly in the liver; and a multi-arm Phase II clinical trial of the Delcath chemosaturation system with melphalan in patients with primary and metastatic liver cancer, which comprise neuroendocrine tumors, hepatocellular carcinoma, ocular or cutaneous melanoma, and metastatic adenocarcinoma. Delcath Systems, Inc. was founded in 1988 and is based in New York, New York.